> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Portola Pharma Gains FDA OK for Blood Thinner
- URL: https://www.fdaweb.com/portola-pharma-gains-fda-ok-for-blood-thinner/
- Published: 2017-06-23T12:00:00.000Z
- Updated: 2026-09-14T22:31:09.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5139017

FDA has approved a Portola Pharma NDA for Bevyxxa (betrixaban) for preventing venous thromboembolism (VTE) in adult patients hospitalized for an acute medical illness who are at risk for thromboembolic complications due to moderate or severe restricted mobility and other risk factors for VTE. An FDA [notice](http://links.govdelivery.com/track?type=click&enid=ZWFzPTEmbWFpbGluZ2lkPTIwMTcwNjIzLjc1MDQ0OTAxJm1lc3NhZ2VpZD1NREItUFJELUJVTC0yMDE3MDYyMy43NTA0NDkwMSZkYXRhYmFzZWlkPTEwMDEmc2VyaWFsPTE3NDI2NTc4JmVtYWlsaWQ9ZGF2aWRAZmRhd2ViLmNvbSZ1c2VyaWQ9ZGF2aWRAZmRhd2ViLmNvbSZmbD0mZXh0cmE9TXVsdGl2YXJpYXRlSWQ9JiYm&&&100&&&https://go.usa.gov/xNfmU?source=govdelivery&utm%5Fmedium=email&utm%5Fsource=govdelivery) says the most common adverse reactions (more than 5%) with betrixaban were related to bleeding. Overall, 54% of patients receiving betrixaban experienced at least one adverse reaction compared with 52% taking enoxaparin. The frequency of patients reporting serious adverse reactions was similar between betrixaban (18%) and enoxaparin (17%). To view the approved label, click [here](https://www.accessdata.fda.gov/drugsatfda%5Fdocs/label/2017/208383s000lbl.pdf?ref=fdaweb.com).